Are Peptides Legal in The US?
FDA Rules, Compounding Status & 2026 Updates Explained
Peptide legality in the US isn’t a simple yes-or-no answer — it depends on which peptide, where it came from, who prescribed it, and what it’s intended for. The FDA’s compounding classification system changed significantly in 2023, a major regulatory announcement arrived in February 2026, and formal rule changes may still be coming. This guide explains exactly where the law stands as of March 2026, which peptides you can legally access and how, and why “available online” is not the same as “legal.”
Key takeaways
- Peptide legality depends on three factors: FDA approval status, compounding eligibility, and how the peptide was obtained.
- FDA-approved peptide drugs — including semaglutide, tirzepatide, and tesamorelin — are fully legal with a valid prescription from a licensed physician.
- Compounded peptides are legal only when prepared by a licensed pharmacy using a substance on the FDA’s Category 1 bulk drug list, dispensed under a physician’s prescription.
- As of March 2026, 19 peptides remain on the FDA’s Category 2 list, which prohibits licensed pharmacies from compounding them.
- On February 27, 2026, HHS Secretary RFK Jr. announced intent to return approximately 14 of those 19 to Category 1 — but no formal FDA rulemaking has been published. Category 2 status remains legally binding today.
- “Research use only” (RUO) peptides are not legal for human consumption, regardless of how easily they can be purchased online.
Before you start This article covers regulatory and legal status as of March 2026 — not medical advice. Verify any peptide’s current classification at FDA.gov before prescribing, dispensing, or using any compounded substance. Regulatory status can change; no online guide replaces a current FDA.gov check.
Three Pathways that Define Legality
Peptide legality in the US runs through three distinct legal pathways. Which pathway applies to your situation determines whether your access is fully legal, prohibited, or illegal for human use.
Pathway 1 — FDA-approved drugs. Peptides that completed the full FDA drug approval process (New Drug Application or Biologics License Application) are legal with a valid prescription. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and tesamorelin (Egrifta) are examples. Each went through Phase I, II, and III clinical trials establishing safety and efficacy before approval.
Pathway 2 — Compounded peptides. Licensed compounding pharmacies can legally prepare certain peptides for individual patients under a physician’s prescription — but only if the peptide’s bulk drug substance appears on the FDA’s Category 1 list. Sermorelin has relatively strong legal standing here due to its prior FDA approval history. As of March 2026, 19 peptides remain on Category 2, which blocks pharmacies from compounding them regardless of physician intent.
Pathway 3 — Research-use-only (RUO). Peptides sold online labeled “not for human consumption” are not legal for human use. That label is a vendor strategy, not a legal shield. Purchasing RUO peptides and self-administering them is not a protected activity under US law.
The FDA’s authority over all three categories comes from the Federal Food, Drug, and Cosmetic Act (FD&C Act), which defines any substance intended to diagnose, treat, cure, or prevent disease as a drug. That definition applies to peptides regardless of how they’re labeled or sold.
Learn more about the difference between FDA-approved drugs and compounded peptides.
How the FDA Classifies Peptides for Compounding
The FDA classifies peptides used in compounding under a three-category interim system established under Sections 503A and 503B of the FD&C Act. These sections govern two distinct types of compounding pharmacies.
Section 503A covers traditional compounding pharmacies that prepare patient-specific medications under a valid physician’s prescription. These pharmacies must source bulk drug substances from FDA-registered manufacturers and provide a certificate of analysis (COA) for each batch. Peptides must meet USP 797 (sterile preparations) and USP 795 (non-sterile preparations) quality standards.
Section 503B covers outsourcing facilities that produce larger batches — sometimes without patient-specific prescriptions — for hospitals and healthcare facilities. These face stricter FDA inspection and manufacturing requirements than 503A pharmacies.
Both 503A and 503B pharmacies are restricted to using peptides that appear on the Category 1 bulk drug list. Category 2 is off-limits to both.
Learn more about how 503A and 503B compounding pharmacies operate under FDA oversight.
Category 1 vs. Category 2 — What the Difference Means for You
The FDA’s Category 1 and Category 2 designations are the most practically important legal distinctions for patients and providers. Here is what each means:
| Category 1 | Category 2 | |
|---|---|---|
| Definition | Under active FDA evaluation; no disqualifying safety concerns identified | Flagged for significant safety concerns |
| Compounding eligibility | Yes — 503A and 503B pharmacies may compound with valid Rx | No — compounding prohibited |
| Example peptides | Sermorelin, NAD+, GHK-Cu (topical only), Gonadorelin | BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604 |
| FDA enforcement posture | Does not intend to take action against compliant pharmacies | May take enforcement action against compounders |
| Legal status for patients | Accessible via licensed pharmacy and physician Rx | Not accessible through licensed US compounding channels |
The FDA placed 19 peptides on Category 2 in September 2023. The stated basis was concerns about immunogenicity risk, manufacturing impurities, and insufficient large-scale human trial data. The classification reflects a data gap — not documented evidence of harm in clinical settings.
Learn more about how Category 1 compounding works and which pharmacies can legally prepare these peptides.
“Research Use Only” Peptides — Why that Label isn’t a Legal Shield
Vendors sell peptides online labeled “for research use only — not for human consumption.” This framing attempts to sidestep the FDA’s drug regulation trigger, which applies to substances intended for human use.
The FDA has confirmed this labeling does not exempt vendors or buyers from FD&C Act requirements. In 2023 and 2024, the FDA issued warning letters to companies selling peptides with RUO labels while simultaneously providing syringes, diluent, and explicit human-use guidance. Courts have upheld that when the context of sale signals human use, the substance is regulated as a drug regardless of the label.
For buyers, purchasing RUO peptides transfers all legal and safety risk to you. No manufacturer liability applies. No quality guarantee exists. No adverse event reporting pathway is available. Insurance coverage for medical complications may be denied.
Important: Online availability does not determine legal status. A peptide appearing at the top of a search results page does not mean it’s legal for human use in the US.
Learn more about the FDA’s enforcement approach to RUO peptide vendors.
Can Doctors Legally Prescribe Peptides?
Physicians can prescribe FDA-approved peptide drugs for their labeled indications or, in some cases, off-label. For example, a physician may prescribe tesamorelin (FDA-approved for HIV-associated lipodystrophy) off-label for a different indication — this is legal, though the physician assumes additional liability in doing so.
Physicians cannot prescribe Category 2 compounded peptides through licensed US pharmacies. Some practitioners refer patients to gray-market compounding operations or advise patients to purchase RUO peptides themselves, distancing the provider from direct prescribing. These arrangements carry significant malpractice and medical board liability for the provider.
Learn more about physician liability when prescribing compounded peptides off-label.
The 2026 Reclassification Update — What RFK Jr.’s Announcement Actually Means
Key takeaways for this section
- On February 27, 2026, HHS Secretary RFK Jr. stated that approximately 14 of the 19 Category 2 peptides are expected to return to Category 1.
- This announcement does not change any peptide’s current legal status.
- Formal reclassification requires an FDA Federal Register publication — none has been issued as of March 2026.
- Compounding pharmacies that begin preparing Category 2 peptides before formal rulemaking accept full enforcement risk.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on The Joe Rogan Experience (Episode #2461) and stated that approximately 14 of the 19 Category 2 peptides are expected to return to Category 1. Kennedy indicated the FDA would announce formal action within weeks.
What this announcement does not do:
- It does not change the legal status of any peptide.
- It does not authorize compounding pharmacies to begin preparing Category 2 peptides.
- It does not constitute a Federal Register rulemaking — the only mechanism that produces binding regulatory change.
Kennedy’s announcement is an accurate signal of the current administration’s regulatory intent. Formal reclassification requires the FDA to publish an updated list in the Federal Register. Until that publication, Category 2 status remains the binding legal standard.
Legal caution: Compounding pharmacies that begin preparing Category 2 peptides before formal reclassification is published in the Federal Register accept full enforcement risk under the FD&C Act.
Peptides cited in reclassification discussions (based on industry and regulatory expert analysis of available safety data):
BPC-157, TB-500 (Thymosin Beta-4), Thymosin Alpha-1, KPV, AOD-9604, MOTS-C, GHK-Cu (injectable), Epitalon, Semax, Selank, Kisspeptin-10, DSIP, and Ipamorelin are the compounds most frequently cited as candidates for return to Category 1.
Approximately five compounds — including Melanotan II, GHRP-2, GHRP-6, CJC-1295, and Cathelicidin LL-37 — are expected to remain on Category 2 due to more specific safety concerns.
Learn more about how the Federal Register rulemaking process works and what to watch for.
Which Specific Peptides are Legal Right Now?
Status as of March 2026. All “expected reclassification” designations reflect industry analysis of the February 27, 2026 HHS announcement — not confirmed FDA action. Verify current status at FDA.gov before prescribing or dispensing any compound.
| Peptide | FDA status | Compounding status (March 2026) | Expected reclassification? | Legal access path |
|---|---|---|---|---|
| Semaglutide | FDA-approved (Ozempic, Wegovy) | Only during declared drug shortage | Not applicable | Rx through licensed pharmacy (brand) |
| Tirzepatide | FDA-approved (Mounjaro, Zepbound) | Only during declared drug shortage | Not applicable | Rx through licensed pharmacy (brand) |
| Tesamorelin | FDA-approved (Egrifta) | Not required — brand available | Not applicable | Rx through licensed physician |
| Sermorelin | Prior FDA approval (withdrawn from market); Category 1 standing | Yes — 503A compoundable | Not applicable | Rx through licensed 503A pharmacy |
| BPC-157 | Not FDA-approved | Prohibited — Category 2 | Yes (expected) | None until rulemaking published |
| TB-500 | Not FDA-approved | Prohibited — Category 2 | Yes (expected) | None until rulemaking published |
| CJC-1295 | Not FDA-approved | Prohibited — Category 2 | No (expected to remain Category 2) | None |
| Ipamorelin | Not FDA-approved | Prohibited — Category 2 | Yes (expected) | None until rulemaking published |
| AOD-9604 | Not FDA-approved; holds FDA GRAS food status | Prohibited — Category 2 | Yes (expected) | None until rulemaking published |
| Semax | Not FDA-approved in US | Prohibited — Category 2 | Yes (expected) | None until rulemaking published |
| GHK-Cu | Category 1 (topical only) | Yes for topical; injectable prohibited | Injectable version expected Category 1 | Rx through licensed 503A pharmacy (topical) |
Important: All “expected” reclassification designations are speculative until the FDA publishes a formal updated list. Verify current status at FDA.gov before prescribing or dispensing any compound.
Learn more about how to verify a peptide’s current compounding status.
Legal Risks of Unapproved Peptides
Key takeaways for this section
- RUO peptides carry no sterility guarantee — independent testing has found purity ranging from 30% to 99% in black-market samples.
- Physicians who prescribe or facilitate access to Category 2 compounded peptides face malpractice exposure and state medical board action.
- Distributing unapproved drugs — including RUO-labeled peptides sold with human-use context — is a federal violation carrying fines, seizure, and potential criminal prosecution.
Using, prescribing, or selling unapproved peptides creates three distinct categories of legal and safety risk.
For patients. Unregulated RUO peptides carry no sterility guarantee and no verified purity. Independent testing of black-market peptide products has found purity ranging from 30% to 99% in tested samples. Contamination risks include bacterial agents that cause sepsis risk, heavy metals including lead and arsenic, and peptide chain fragments that can trigger immune reactions. No manufacturer liability applies when products are labeled “not for human consumption.” Insurance coverage for treatment of complications may be denied.
For providers. Physicians who prescribe or facilitate patient access to Category 2 compounded peptides face malpractice exposure and state medical board disciplinary action. Providers who order peptides in bulk without patient-specific prescriptions violate FD&C Act misbranding and adulteration provisions. The FDA’s 2024 enforcement action against Tailor Made Compounding highlighted how bulk-ordering arrangements without patient-specific prescriptions trigger federal enforcement.
For sellers. Distributing unapproved drugs — including peptides labeled as RUO while sold with human-use context — is a federal violation under the FD&C Act. Penalties include warning letters, product seizure, injunctions, and criminal prosecution carrying fines and imprisonment. The FDA issued warning letters to online peptide vendors in 2023 and 2024 for this pattern.
Learn more about FDA enforcement actions against compounding pharmacies and online peptide vendors.
Are Peptide Supplements Legal?
Products labeled as “peptide dietary supplements” — including oral BPC-157, GHK-Cu capsules, or any synthetic peptide sold as a supplement — are not legally compliant. The Dietary Supplement Health and Education Act (DSHEA) requires that supplement ingredients be recognized dietary ingredients. Synthetic peptides do not qualify.
The FDA has confirmed there is no legal basis for selling BPC-157 as a drug, food, or dietary supplement, and has issued warning letters to companies attempting to do so.
Cosmetic peptides occupy a separate regulatory category. Topical peptides in skincare products that make no therapeutic claims are regulated as cosmetics, not drugs, as long as no disease-treatment claims appear on the label.
Learn more about the FDA’s regulatory distinction between cosmetic and therapeutic peptide products.
Are Peptides Banned in Sports?
The World Anti-Doping Agency (WADA) operates independently of the FDA. A peptide can be legal to possess in the US and simultaneously banned for athletes in tested sports.
WADA’s Prohibited List bans:
- All growth hormone secretagogues — including GHRP-2, GHRP-6, CJC-1295, Ipamorelin, and Sermorelin — under the S2 category (Peptide Hormones, Growth Factors, Related Substances)
- BPC-157 under the S0 category (Non-Approved Substances) since January 2022
- IGF-1 analogs, growth hormone releasing hormones, and related peptide classes
If you’re subject to WADA testing, assume all peptides are prohibited unless you can verify otherwise through your sport’s anti-doping organization. The FDA’s Category 1 reclassification of any peptide does not affect WADA’s prohibition of that same compound.
Learn more about WADA’s Prohibited List and how it applies to compounded peptides.
How to Legally Obtain Peptides in the US
Two legal pathways exist for patients seeking peptides in the US.
Pathway 1 — FDA-approved peptides. Consult a licensed physician. If they determine a peptide drug is clinically appropriate, they can write a prescription. A licensed pharmacy then dispenses the brand-name product. This applies to semaglutide, tirzepatide, tesamorelin, and other FDA-approved peptide drugs. Insurance coverage varies by plan and indication.
Pathway 2 — Compounded Category 1 peptides. Consult a licensed physician. If the peptide appears on the Category 1 list, a licensed 503A compounding pharmacy can prepare a patient-specific formulation under that prescription. Sermorelin is the most commonly accessed peptide through this pathway.
To verify that a compounding pharmacy is operating legally, confirm all of the following:
- The pharmacy holds a current state pharmacy license
- The pharmacy sources bulk drug substance APIs from FDA-registered manufacturers
- The pharmacy provides a certificate of analysis (COA) with a specific lot number for each dispensed compound
- The pharmacy operates under USP 797/795 standards for sterile and non-sterile preparations
- The specific peptide appears on the FDA’s Category 1 list at FDA.gov
Purchasing online is not a legal pathway. Online availability does not determine legal status. Buying from a website does not create the physician prescription, licensed pharmacy dispensing, or Category 1 compounding framework required for legal access.
Learn more about how to find a licensed compounding pharmacy and verify their credentials.
International Peptide Regulations
The US framework is among the more permissive globally for personal possession of unapproved peptides — possession itself is not criminalized at the federal level. Other major markets require prescription access or restrict peptides more actively.
| Country / Region | Governing body | Classification | Legal access |
|---|---|---|---|
| USA | FDA (CDER), FD&C Act | FDA-approved Rx or Category 1 compounded Rx; Category 2 prohibited for compounding; RUO possession not criminalized | Licensed physician Rx; licensed 503A pharmacy for Category 1 |
| Australia | TGA (Therapeutic Goods Administration) | Prescription-only; importation controlled with active customs enforcement | Physician Rx required; customs seizures of imported peptides documented |
| Canada | Health Canada | Prescription-required; limited licensed access; importation restricted | Physician Rx; limited licensed pharmacy access |
| UK | MHRA (Medicines and Healthcare products Regulatory Agency) | Prescription-only medicine classification; personal importation controlled | Physician Rx required |
| EU | EMA (European Medicines Agency) + national bodies | Clinical trial or approval required; member states apply national pharmaceutical law | Varies by member state; generally requires approval or clinical trial enrollment |
Athletes in all five jurisdictions are subject to WADA prohibition of peptide classes regardless of domestic possession rules.
Learn more about how international peptide import enforcement compares to US regulations.
The Bottom Line
Peptide legality in the US comes down to three questions: Is the peptide FDA-approved as a drug? If not, is it on the Category 1 compounding list? And did it come from a licensed pharmacy under a physician’s prescription? If the answer to all three is no, you’re outside the legal framework — regardless of what a website or a podcast says. The February 2026 HHS announcement signals that reclassification is coming for many Category 2 peptides, but “coming” is not “done” — and no formal FDA action has been published. Your best step right now is to consult a licensed physician who can tell you which options are legally accessible for your specific situation today, and monitor FDA.gov for formal rule changes.
Frequently Asked Questions
Can I legally use peptides for anti-aging or skin health?
Yes, for topical cosmetic products — no, for systemic or injectable use without a prescription. Topical cosmetic peptides in skincare products that make no therapeutic claims are regulated as cosmetics and are legal without a prescription. Therapeutic anti-aging peptides used by injection or taken systemically require a physician’s prescription and must come from a licensed pharmacy. OTC injectable “anti-aging” peptides are not legally compliant under FDA rules.
Are peptides banned entirely in the US?
No. FDA-approved peptide drugs and Category 1 compounded peptides are fully legal with a valid physician’s prescription. Category 2 status restricts compounding — it does not criminalize personal possession of the molecule. The FDA’s restrictions target compounding pharmacies and sellers, not patients holding peptides for personal use. Nineteen specific peptides are currently ineligible for licensed compounding and may be reclassified following formal FDA rulemaking.
What happens if a pharmacy compounds Category 2 peptides?
The pharmacy risks FDA warning letters, product seizure, and federal enforcement action under the FD&C Act for misbranding and adulteration. State boards of pharmacy may take independent disciplinary action. Providers who prescribe through these pharmacies face malpractice exposure and state medical board scrutiny.
Are biohacking peptides like Semax or Selank legal?
No, not through licensed US channels. Semax and Selank are currently Category 2 — they cannot be legally compounded by US licensed pharmacies. Both are among the peptides cited in the February 2026 HHS reclassification discussions. Until the FDA publishes a formal updated list, they remain Category 2. They are available as RUO products online, but purchasing and using RUO peptides does not make them legal for human use.
Is it legal to import peptides from overseas for personal use?
No guarantee of legal entry exists. The FDA’s personal importation policy does not protect unapproved drug products. Customs and Border Protection may seize imported peptide shipments. Importing for resale is a federal violation. Individual enforcement varies, but no legal protection exists for importing Category 2 peptides regardless of quantity.
How do I verify that a peptide is legally compounded?
Request a certificate of analysis (COA) with a specific lot number from the pharmacy for each dispensed product. Confirm the pharmacy holds current state licensure. Verify that the peptide’s API was sourced from an FDA-registered manufacturer. Cross-check the compound against the Category 1 list at FDA.gov. Confirm the pharmacy follows USP 797/795 standards. If the pharmacy cannot document all of these, the compound’s legal standing is questionable.
Does the RFK Jr. announcement mean I can now access Category 2 peptides?
No — not yet. An announcement of regulatory intent is not a regulatory action. Formal reclassification requires the FDA to publish an updated list in the Federal Register. Until that happens, Category 2 status is the binding legal standard. Monitor FDA.gov for a formal notice.
Considering peptide therapy? Speak with a licensed physician who can review your labs and discuss whether any option is appropriate for your situation and currently accessible through legal channels.
References
- U.S. Food & Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 list). Updated 2023. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- U.S. Food & Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. Final guidance, January 7, 2025. Federal Register. https://www.federalregister.gov/documents/2025/01/07/2024-31546/
- The Joe Rogan Experience. Episode #2461. Robert F. Kennedy Jr. February 27, 2026.
- Frier Levitt. FDA Peptide Regulation May Shift: What RFK Jr.’s Announcement Means for Compounding Pharmacies. March 2026. https://www.frierlevitt.com/articles/fda-peptide-regulation-rfk-announcement-compounding-pharmacies/
- U.S. Anti-Doping Agency (USADA). BPC-157: Experimental Peptide Creates Risk for Athletes. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
- World Anti-Doping Agency. 2022 Prohibited List. https://www.wada-ama.org/en/prohibited-list
- Holt Law. Regulatory Alert: The Legal Status of BPC-157 in Compounding and Clinical Practice. https://djholtlaw.com/regulatory-alert-the-legal-status-of-bpc-157-in-compounding-and-clinical-practice/
- LumaLex Law. RFK Jr., Peptides & FDA Category 2: What’s Really Changing? March 2026. https://www.lumalexlaw.com/2026/03/02/fda-category-2-peptides-reclassification/
- PubMed citations for individual peptide mechanism claims (Sermorelin, tesamorelin, semaglutide GLP-1 mechanism) and for the FDA’s 2023 Category 2 designation basis — flagged for physician review and primary source PMID verification before publication. See post-output note.
Compliance disclaimer
The information on this page is for educational purposes only. We do not provide medical advice, diagnosis, or treatment. Peptide legality in the USA is determined by FDA classification, compounding pharmacy eligibility, and intended use — all of which may change as the FDA processes the expected 2026 reclassification. This page reflects the legal status as of March 2026 and will be updated when the FDA publishes a formal Federal Register notice. No statement on this page constitutes legal advice. Consult a licensed attorney and a licensed physician before making decisions based on this information. All compounded peptides must be obtained through licensed pharmacies compliant with FDCA Sections 503A and 503B.